FIELD: biotechnology.
SUBSTANCE: invention can be used in medical practice. The invention discloses a biologically active single-chain relaxin peptide, which is characterized by the following formula (I): Ac-X10-E-G-R-E-X15-V-R-X18-X19-I-X21-X22-E-G-X25-S-X27-X28-X29-X30-X31-X32-X33-NH2.
EFFECT: invention has agonist activity against the relaxin receptor (RXFP1) and can be used to obtain a medicinal product for the treatment of various cardiovascular diseases associated with dysfunction and disturbances in RXFP1 activation.
28 cl, 6 ex, 9 tbl, 2 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION CONTAINING INSULIN AND GLUCAGON | 2019 |
|
RU2823246C2 |
| LONG-ACTING CO-AGONISTS OF GLUCAGON AND GLP-1 RECEPTORS | 2018 |
|
RU2779314C2 |
| PEPTIDIC INTERLEUKIN-23 RECEPTOR INHIBITORS FOR ORAL ADMINISTRATION AND USE THEREOF FOR TREATING INFLAMMATORY INTESTINAL DISEASES | 2015 |
|
RU2736637C2 |
| PEPTIDE ANALOG OF ACYLATED OXYNTOMODULIN | 2018 |
|
RU2752787C1 |
| GIP AGONIST COMPOUNDS AND METHODS | 2015 |
|
RU2716985C2 |
| ACYLATED DOUBLE AGONISTS OF GLP-1/GLP-2 | 2017 |
|
RU2753193C2 |
| NOVEL OXYNTOMODULIN DERIVATIVES AND A PHARMACEUTICAL COMPOSITION CONTAINING THEM FOR TREATING OBESITY | 2012 |
|
RU2739209C2 |
| TREATMENT OF NEUROLOGICAL DISEASES | 2017 |
|
RU2755997C2 |
| COMPOSITION FOR TREATING HYPERLIPIDEMIA CONTAINING AN OXYNTOMODULIN DERIVATIVE | 2013 |
|
RU2768853C1 |
| SOLID COMPOSITIONS FOR ORAL ADMINISTRATION | 2018 |
|
RU2777206C2 |
